Premium
Inhaled sodium metabisulphite induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate.
Author(s) -
Dixon CM,
Ind PW
Publication year - 1990
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1990.tb03786.x
Subject(s) - nedocromil sodium , bronchoconstriction , nedocromil , sodium , pharmacology , placebo , chemistry , sodium cromoglycate , cromolyn sodium , dose , asthma , medicine , alternative medicine , organic chemistry , pathology
1. The effects of nedocromil sodium and sodium cromoglycate on bronchoconstriction induced by inhaled sodium metabisulphite have been studied in eight atopic subjects, three of whom had mild asthma. 2. Nedocromil sodium (4 mg, 7.8 × 10(‐6) M), sodium cromoglycate (10 mg, 24.1 × 10(‐6) M) and matched placebo were administered by identical metered dose inhalers 30 min before a dose‐response to sodium metabisulphite (5‐100 mg ml‐1) was performed. 3. Maximum fall in sGaw after placebo pre‐treatment was ‐43.9 +/− 3.3% baseline (mean +/− s.e. mean). At the same metabisulphite concentration maximum fall in sGaw after sodium cromoglycate was ‐13.0 +/− 3.6% and after nedocromil sodium was +4.3 +/− 6.8%. Nedocromil sodium prevented any significant fall in sGaw even after higher concentrations of metabisulphite. 4. Both nedocromil sodium, 4 mg, and sodium cromoglycate, 10 mg, inhibited sodium metabisulphite induced bronchoconstriction but nedocromil sodium was significantly more effective. Relative in vivo potency of the two drugs is broadly in line with other in vivo and in vitro studies.